Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly is on the verge of becoming the world's first pharmaceutical company to reach a market value of $1 trillion. This ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Lilly's long-term growth prospects make the stock a great pick. Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for ...

The investment seeks to build upon Lilly's success from Mounjaro and Zepbound, which are riding a wave of popularity in so-called GLP-1 drugs. Lilly has 11 obesity drugs in its pipeline and wants ...

OpenAI closed its funding round at a $157 billion valuation. Tesla shares dropped after the EV maker missed estimates on ...